Hero

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

1

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

2

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Bringing breakthrough pioneering therapies to patients with life-threatening diseases

3

Bringing breakthrough pioneering therapies to patients with life-threatening diseases

Celyad issues a White Paper about CAR T NKR-2

4

Celyad issues a White Paper about CAR T NKR-2

About Celyad

Making the impossible possible for the patient

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

More info about Celyad

Latest News

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies

Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies

Discover all news

Carousel

Social Feed